Point Loma Resources Ltd News - PLX

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

CARMIEL, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that senior...

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

CARMIEL, Israel, May 8, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Dr. David...

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

CARMIEL, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the Mexican...

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of

CARMIEL, Israel, April 2, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first...

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

NEW YORK and CARMIEL, Israel, March 18, 2013 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE MKT:PLX...

Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered C

CARMIEL, Israel, March 7, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that it has received...

Protalix Announces New Clinical Data on ELELYSO(TM) to be Presented at the WORLD Symposium 2013

CARMIEL, Israel, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that new clinical...

Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX) (TASE:PLX), confirms, in response to inquiries...

Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

CARMIEL, Israel, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) today announced that Dr. David...

Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Netwo

CARMIEL, Israel, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Point Loma Resources Ltd (PLX)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PLX News

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered C

Protalix Announces New Clinical Data on ELELYSO(TM) to be Presented at the WORLD Symposium 2013

Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Netwo

Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102

Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)

Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

Protalix BioTherapeutics to Present at the 2012 Jefferies Global Healthcare Conference in London

European Commission Issues Decision on Taliglucerase Alfa Marketing Authorization Application

PLX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Point Loma Resources Ltd (PLX) News

Point Loma Resources Ltd (PLX)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PLX News

Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences

Protalix BioTherapeutics to Present at the Oppenheimer 14th Annual Israeli Conference

UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease

Protalix BioTherapeutics Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of

UPLYSO(TM) (alfataliglicerase) Approved in Brazil by ANVISA for the Treatment of Gaucher Disease

Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients With PRX-112, an Orally-Administered C

Protalix Announces New Clinical Data on ELELYSO(TM) to be Presented at the WORLD Symposium 2013

Protalix BioTherapeutics Reviewing Partnering and Other Alternatives

Protalix BioTherapeutics to Present at the 15th Annual BIO CEO & Investor Conference

Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Netwo

Protalix BioTherapeutics Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102

Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO(TM) (taliglucerase alfa)

Protalix BioTherapeutics to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York City

Protalix BioTherapeutics to Present at the 2012 Jefferies Global Healthcare Conference in London

European Commission Issues Decision on Taliglucerase Alfa Marketing Authorization Application

PLX Discussion

Your Recent History